Literature DB >> 11403992

Orphanin FQ/nociceptin binds to functionally coupled ORL1 receptors on human immune cell lines and alters peripheral blood mononuclear cell proliferation.

J Peluso1, C Gavériaux-Ruff, H W Matthes, D Filliol, B L Kieffer.   

Abstract

Orphanin FQ/nociceptin (OFQ/N) has been shown to modulate nociception, responses to stress and anxiety. We investigated OFQ/N function in human immune cells. We find that monocytic U937, T lymphocytic CEM, and MOLT-4 cell lines express OFQ/N binding sites at levels comparable to that of human SH-SY5Y neuroblastoma cells. We show that OFQ/N receptors are functionally coupled to G proteins in these cells. Finally OFQ/N decreases proliferation of phytohemagglutinin-stimulated peripheral blood mononuclear cells in vitro at doses ranging from 10(-13) to 10(-8) M. Thus, our data suggest that OFQ/N and OFQ/N receptor may act as an immunomodulatory system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403992     DOI: 10.1016/s0361-9230(01)00482-8

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  12 in total

Review 1.  Opioid receptors and signaling on cells from the immune system.

Authors:  Jean M Bidlack; Maxim Khimich; Amy L Parkhill; Sarah Sumagin; Baoyong Sun; Christopher M Tipton
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-08       Impact factor: 4.147

Review 2.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

3.  [Expression und function of the ORL-1 receptor on human leukocytes].

Authors:  C Krüger; L Köthe; A Struppert; C Pietruck; A Simm; S Grond
Journal:  Schmerz       Date:  2006-11       Impact factor: 1.107

4.  Nociceptin/orphanin FQ suppresses adaptive immune responses in vivo and at picomolar levels in vitro.

Authors:  Benito Anton; Phillipe Leff; Joseph J Meissler; Juan C Calva; Rodolfo Acevedo; Alberto Salazar; Maura Matus; Anabel Flores; Martin Martinez; Martin W Adler; John P Gaughan; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2010-02-02       Impact factor: 4.147

5.  Orphanin FQ/nociceptin activates nuclear factor kappa B.

Authors:  Courtney L Donica; Vanessa I Ramirez; Hibah O Awwad; Nurulain T Zaveri; Lawrence Toll; Kelly M Standifer
Journal:  J Neuroimmune Pharmacol       Date:  2011-05-06       Impact factor: 4.147

6.  Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists.

Authors:  Anika Mann; Lionel Moulédous; Carine Froment; Patrick R O'Neill; Pooja Dasgupta; Thomas Günther; Gloria Brunori; Brigitte L Kieffer; Lawrence Toll; Michael R Bruchas; Nurulain T Zaveri; Stefan Schulz
Journal:  Sci Signal       Date:  2019-03-26       Impact factor: 8.192

7.  The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis.

Authors:  Dickson Carvalho; Fabricia Petronilho; Francieli Vuolo; Roberta Albino Machado; Larissa Constantino; Remo Guerrini; Girolamo Calo; Elaine Cristina Gavioli; Emílio Luiz Streck; Felipe Dal-Pizzol
Journal:  Intensive Care Med       Date:  2008-10-10       Impact factor: 17.440

Review 8.  Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.

Authors:  Courtney L Donica; Hibah O Awwad; Deepak R Thakker; Kelly M Standifer
Journal:  Mol Pharmacol       Date:  2013-02-08       Impact factor: 4.436

9.  Suppression of CCL2/MCP-1 and CCL5/RANTES expression by nociceptin in human monocytes.

Authors:  David E Kaminsky; Thomas J Rogers
Journal:  J Neuroimmune Pharmacol       Date:  2007-09-15       Impact factor: 4.147

10.  Increased nociceptin/orphanin FQ plasma levels in hepatocellular carcinoma.

Authors:  Ferenc Szalay; Monika B Hantos; Andrea Horvath; Peter L Lakatos; Aniko Folhoffer; Kinga Dunkel; Dalma Hegedus; Kornelia Tekes
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.